Icotinib, a first-generation EGFR TKI, is being evaluated for its efficacy in treating advanced non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. This study addresses a significant unmet medical need, as current EGFR inhibitors primarily target common mutations (e.g., 19 del and 21 L858R). The market for NSCLC therapies is substantial, with increasing demand for targeted therapies that can address diverse mutation profiles. If successful, icotinib could capture a niche segment of the NSCLC market, particularly in regions with high prevalence of uncommon mutations. Competitive implications include potential differentiation from existing therapies and the opportunity to establish a first-mover advantage in this specific patient population. Diligence considerations should focus on the drug's safety profile, efficacy data, and potential regulatory pathways in various markets.